SCHEMBL514536

SCHEMBL514536

C=CCCCCC(=O)CCCC

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.56
ALDH1A1 P00352 3/20 0.54
MAPT P10636 3/20 0.54
ABCC4 O15439 1/20 0.54
LMNA P02545 2/20 0.52
FAAH O00519 3/20 0.48
KMT2A Q03164 1/20 0.48
GMNN O75496 1/20 0.44
USP2 O75604 1/20 0.44
CYP1A2 P05177 1/20 0.44
POLB P06746 1/20 0.44
CYP2C9 P11712 1/20 0.44
ALOX15 P16050 1/20 0.44
APEX1 P27695 1/20 0.44
CYP2C19 P33261 1/20 0.44
RECQL P46063 1/20 0.44
BLM P54132 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
HSD17B10 Q99714 1/20 0.44
DUSP3 P51452 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL515048 0.98 TSHR (0.60) TSHRALDH1A1MAPTABCC4LMNA
SCHEMBL21494961 0.98 TSHR (0.60) TSHRALDH1A1MAPTABCC4LMNA
SCHEMBL515429 0.98 TSHR (0.60) TSHRALDH1A1MAPTABCC4LMNA
SCHEMBL11114323 0.94 TSHR (0.67) TSHRALDH1A1MAPTABCC4LMNA
SCHEMBL21983976 0.94 TSHR (0.67) TSHRALDH1A1MAPTABCC4LMNA
SCHEMBL25340388 0.94 TSHR (0.67) TSHRALDH1A1MAPTABCC4LMNA
SCHEMBL11746496 0.94 TSHR (0.67) TSHRALDH1A1MAPTABCC4LMNA
SCHEMBL24090416 0.94 TSHR (0.67) TSHRALDH1A1MAPTABCC4LMNA
SCHEMBL25340115 0.94 TSHR (0.67) TSHRALDH1A1MAPTABCC4LMNA
SCHEMBL9513739 0.94 TSHR (0.67) TSHRALDH1A1MAPTABCC4LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102369173-B Method for producing high-purity terminal olefin compound KURARAY CO 2014-09-10 CN disclosed
EP-2415740-B1 METHOD FOR PRODUCING HIGH-PURITY TERMINAL OLEFIN COMPOUND KURARAY CO (JP) 2013-12-25 EP disclosed
US-8609886-B2 Method for producing high purity terminal olefin compound KURARAY CO., LTD. (JP) 2013-12-17 US disclosed
CN-102369173-A Method for producing high-purity terminal olefin compound KURARAY CO 2012-03-07 CN disclosed
EP-2415740-A1 METHOD FOR PRODUCING HIGH-PURITY TERMINAL OLEFIN COMPOUND Kuraray Co., Ltd. (JP) 2012-02-08 EP disclosed
US-20120029229-A1 METHOD FOR PRODUCING HIGH PURITY TERMINAL OLEFIN COMPOUND KURARAY CO., LTD. (JP) 2012-02-02 US disclosed
US-7714087-B2 Polar group-containing olefin copolymer, process for preparing the same, thermoplastic resin composition containing the copolymer, and uses thereof MITSUI CHEMICALS, INC. (JP) 2010-05-11 US disclosed
EP-1734061-B1 Polar group-containing olefin copolymer, process for preparing the same, thermoplastic resin composition containing the copolymer and uses thereof MITSUI CHEMICALS INC (JP) 2010-04-07 EP disclosed
US-20090137757-A1 Polar group-containing olefin copolymer, process for preparing the same, thermoplastic resin composition containing the copolymer, and uses thereof IMUTA JUNICHI 2009-05-28 US disclosed
US-7393907-B2 Polar group-containing olefin copolymer, process for preparing the same, thermoplastic resin composition containing the copolymer, and uses thereof MITSUI CHEMICALS, INC. (JP) 2008-07-01 US disclosed
CN-100357330-C Polar group-containing olefin copolymer, thermoplastic resin composition containing the copolymer, and uses thereof MITSUI CHEMICALS INC (JP) 2007-12-26 CN disclosed
CN-100335509-C Polar group-containing olefin copolymer, process for preparing the same, thermoplastic resin composition containing the copolymer, and uses thereof MITSUI CHEMICALS INC (JP) 2007-09-05 CN disclosed
EP-1734061-A2 Polar group-containing olefin copolymer, process for preparing the same, thermoplastic resin composition containing the copolymer and uses thereof MITSUI CHEMICALS, INC. (JP) 2006-12-20 EP disclosed
CN-1737017-A Polar group-containing olefin copolymer, process for preparing the same, thermoplastic resin composition containing the copolymer, and uses thereof MITSUI CHEMICALS INC (JP) 2006-02-22 CN disclosed
CN-1737016-A Polar group-containing olefin copolymer, thermoplastic resin composition containing the copolymer, and uses thereof MITSUI CHEMICALS INC (JP) 2006-02-22 CN disclosed
CN-1219800-C Polar group-containing olefin copolymer, thermoplastic resin composition containing the same, and use thereof MITSUI CHEMICALS INC (JP) 2005-09-21 CN disclosed
US-20040122192-A1 Polar group-containing olefin copolymer, process for preparing the same, thermoplastic resin composition containing the copolymer, and uses thereof MITSUI CHEMICALS, INC. 2004-06-24 US disclosed
US-20020156207-A1 Polar group-containing olefin copolymer, process for preparing the same, thermoplastic resin composition containing the copolymer, and uses thereof MITSUI CHEMICALS, INC. (JP) 2002-10-24 US disclosed
CN-1342715-A Polar group-containing olefin copolymer, process for producing the same, thermoplastic resin composition containing the same, and use thereof MITSUI CHEMICALS INC (JP) 2002-04-03 CN disclosed
EP-1186619-A2 Polar group-containing olefin copolymer, process for preparing the same, thermoplastic resin composition contaning the copolymer, and uses thereof Mitsui Chemicals, Inc. (JP) 2002-03-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120029229-A1 METHOD FOR PRODUCING HIGH PURITY TERMINAL OLEFIN COMPOUND ADH1A, ADH1C, OSBP TSHR 3218/4885ALDH1A1 233/4885MAPT 1768/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.